Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has shared an update.
Shanghai Pharmaceuticals Holding Co., Ltd. announced proposed amendments to its Articles of Association and the abolishment of its Supervisory Board, replacing it with an audit committee. These changes align with recent revisions in Chinese corporate and securities laws, aiming to streamline governance and enhance operational efficiency. The amendments are expected to impact the company’s governance structure, potentially influencing its market positioning and stakeholder relations.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, catering to both domestic and international markets.
Average Trading Volume: 3,451,346
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.17B
See more data about 2607 stock on TipRanks’ Stock Analysis page.